dna vaccines

Summary

Summary: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.

Top Publications

  1. ncbi Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
  2. pmc Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus
    Karuppiah Muthumani
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Vaccine 26:5128-34. 2008
  3. pmc Therapeutic HPV DNA vaccines
    Ken Lin
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    Immunol Res 47:86-112. 2010
  4. ncbi Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences
    Agnete Brunsvik Fredriksen
    Institute of Immunology, University of Oslo, Oslo, Norway
    Blood 110:1797-805. 2007
  5. ncbi DNA vaccines: developing new strategies to enhance immune responses
    Shaheed A Abdulhaqq
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Blvd, 505 Stellar Chance Laboratories, Philadelphia, PA, 19104, USA
    Immunol Res 42:219-32. 2008
  6. ncbi Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
  7. pmc Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
    Matthias Tenbusch
    Department of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany
    BMC Immunol 9:13. 2008
  8. pmc DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge
    Margherita Rosati
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, Bldg 535, Rm 210, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    J Virol 79:8480-92. 2005
  9. ncbi Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
  10. ncbi DNA vaccines: a review
    M A Liu
    Transgene, Strasbourg, France
    J Intern Med 253:402-10. 2003

Detail Information

Publications387 found, 100 shown here

  1. ncbi Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
    ..b>DNA vaccines encoding conserved antigens protect animals against diverse subtypes, but their potency needs improvement...
  2. pmc Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus
    Karuppiah Muthumani
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Vaccine 26:5128-34. 2008
    ..Taken together, these data support further study of the use of consensus CHIK antigens in a potential vaccine cocktail...
  3. pmc Therapeutic HPV DNA vaccines
    Ken Lin
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    Immunol Res 47:86-112. 2010
    ..Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.
  4. ncbi Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences
    Agnete Brunsvik Fredriksen
    Institute of Immunology, University of Oslo, Oslo, Norway
    Blood 110:1797-805. 2007
    ..The results suggest that bivalency and foreign sequences combine to increase the efficiency of chemokine-Id DNA vaccines.
  5. ncbi DNA vaccines: developing new strategies to enhance immune responses
    Shaheed A Abdulhaqq
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Blvd, 505 Stellar Chance Laboratories, Philadelphia, PA, 19104, USA
    Immunol Res 42:219-32. 2008
    ..focused our research on understanding the basic biology of and developing novel therapeutic and prophylactic DNA vaccines. We have among others three distinct primary areas of interest which include: 1...
  6. ncbi Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  7. pmc Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
    Matthias Tenbusch
    Department of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany
    BMC Immunol 9:13. 2008
    ..In addition, bicistronic vectors allowing independent expression of the antigen and the cytokine were tested in parallel...
  8. pmc DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge
    Margherita Rosati
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, Bldg 535, Rm 210, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    J Virol 79:8480-92. 2005
    ..Our data show that the combinations of DNA vaccines producing native and modified forms of antigens elicit more balanced immune responses able to significantly ..
  9. ncbi Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...
  10. ncbi DNA vaccines: a review
    M A Liu
    Transgene, Strasbourg, France
    J Intern Med 253:402-10. 2003
    The DNA vaccines are simple rings of DNA containing a gene encoding an antigen, and a promoter/terminator to make the gene express in mammalian cells...
  11. ncbi Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus
    Kristin Spik
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 24:4657-66. 2006
    b>DNA vaccines for Rift Valley fever virus (RVFV), Crimean Congo hemorrhagic fever virus (CCHFV), tick-borne encephalitis virus (TBEV), and Hantaan virus (HTNV), were tested in mice alone or in various combinations...
  12. pmc Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
    W F Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Clin Invest 108:669-78. 2001
    ..Thus, cancer therapy using CRT linked to a tumor antigen holds promise for treating tumors by combining antigen-specific immunotherapy and antiangiogenesis...
  13. pmc Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens
    Dominick J Laddy
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 3:e2517. 2008
    ..We also evaluated the use of in vivo electroporation to deliver these vaccines to overcome the immunogenicity barrier encountered in larger animal models of vaccination...
  14. ncbi Immunogenicity of CTLA4 fusion anti-caries DNA vaccine in rabbits and monkeys
    Rong Jia
    Key Laboratory for Oral Biomedical Engineering of Ministry of Education, School and Hospital of Stomatology, Wuhan University, 237 Luoyu Road, Wuhan 430079, PR China
    Vaccine 24:5192-200. 2006
    ..Here, we show anti-caries DNA vaccines, pGJA-P and pGJA-P/VAX, encoding Streptococcus mutans antigens fused to cytotoxic T lymphocyte antigen-4 (CTLA4)..
  15. ncbi Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
    P J Bergman
    Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA
    Vaccine 24:4582-5. 2006
    ..These studies provided the impetus for development of a xenogeneic DNA vaccine program in CMM...
  16. ncbi DNA vaccines: progress and challenges
    John J Donnelly
    Chiron Vaccines, Chiron Corporation, Emeryville, CA 94608, USA
    J Immunol 175:633-9. 2005
    ..of the initial in vivo demonstration of the ability of plasmid DNA to generate protective immune responses, DNA vaccines have entered into a variety of human clinical trials for vaccines against various infectious diseases and for ..
  17. ncbi Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 168:562-8. 2002
    ..These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4(+) T cell responses and suggest that optimal Th cell priming ..
  18. ncbi Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy
    Roman Bauer
    Department of Molecular Biology, Division of Allergy and Immunology, Hellbrunnerstrasse 34, 5020 Salzburg, Austria
    J Allergy Clin Immunol 118:269-76. 2006
    ..Ubiquitination offers a general approach for the production of hypoallergenic DNA vaccines.
  19. pmc Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques
    Amara Luckay
    Wyeth Vaccines Research, 401 N Middletown Rd, Bldg 180 216 10, Pearl River, NY 10965, USA
    J Virol 81:5257-69. 2007
    ..Collectively, these results have important implications for the design and development of an efficacious vaccine for the prevention of HIV-1 infection...
  20. pmc Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease
    Hong Duck Kim
    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, P O Box 1649, Peoria, IL 61656, USA
    Immunol Lett 112:30-8. 2007
    ....
  21. ncbi Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse
    Reshma Singh
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 175:3663-73. 2005
    ..b>DNA vaccines expressing either a fragment or full-length HER-2/neu were constructed in LLO-fused and non-LLO-fused forms...
  22. ncbi DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV) display enhanced immunogenicity
    Yunbo Jiang
    Laboratory of Animal Virology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, PR China
    Vaccine 24:2869-79. 2006
    ..More importantly, co-expression of GP5 and M protein in heterodimers can significantly improve the potency of DNA vaccination and could be used as a strategy to develop a new generation of vaccines against PRRSV...
  23. pmc FDA guidance on prophylactic DNA vaccines: analysis and recommendations
    Dennis M Klinman
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Vaccine 28:2801-5. 2010
    ..This work describes the evolution of FDA policy over that period, the status of current regulatory guidance, and provides recommendations for further changes to facilitate development in this field...
  24. pmc Developing DNA vaccines that call to dendritic cells
    Michele A Kutzler
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 114:1241-4. 2004
    ..Such cooperative strategies delivering vaccine in a single, simple platform result in improved cellular immunity in vivo, including enhanced tetramer responses and IFN-gamma secretion by antigen-specific cells...
  25. ncbi DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Hum Gene Ther 16:26-34. 2005
    ....
  26. ncbi Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines
    Sudhir P Kasturi
    Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
    Biomaterials 26:6375-85. 2005
    ..presenting cells (APCs) have not been adequately addressed in the rational design of delivery systems for DNA vaccines. Here we report synthesis and characterization of biodegradable microparticles that (a) can passively target ..
  27. ncbi Prime-boost strategies in DNA vaccines
    C Jane Dale
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    Methods Mol Med 127:171-97. 2006
    ..Plasmid DNA vaccines and recombinant fowlpox virus (rFPV) vaccines are promising HIV-1 vaccine candidates, although delivering ..
  28. ncbi Strategies for designing and optimizing new generation vaccines
    J A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1578, USA
    Nat Rev Immunol 1:209-19. 2001
    ..Only recently has vaccinology returned to the realm of immunology, because a new understanding of immune mechanisms has allowed translation of basic discoveries into vaccine strategies...
  29. ncbi Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines
    Karen Colbjørn Larsen
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    Vaccine 27:5589-98. 2009
    ..These results indicate that optimal immunogenicity may require activation of distinct innate immune signalling pathways. Thus this strategy offers a novel route to the discovery of a new generation of adjuvants...
  30. pmc Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity
    Jennifer B Jacob
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer Res 70:119-28. 2010
    ..To overcome immune tolerance to HER-2, we formulated DNA vaccines that express both human HER-2 and heterologous rat Neu sequences in separate plasmids or as single hybrid ..
  31. pmc DNA vaccines for targeting bacterial infections
    Mariana Ingolotti
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Expert Rev Vaccines 9:747-63. 2010
    ..b>DNA vaccines consist of a DNA plasmid containing a transgene that encodes the sequence of a target protein from a pathogen ..
  32. ncbi Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence
    Jing Ni
    Division of Cellular Immunology, German Cancer Research Center DKFZ, Tumor Immunology Program, D 69120 Heidelberg, Germany
    Vaccine 27:5480-7. 2009
    ..After application to the ear pinna and electroporation (EP), CD11cS based DNA vaccines induced specific B- and T-cell responses, including IFN-gamma secretion...
  33. ncbi DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies
    Bertrand Bellier
    UPMC Univ Paris 06, UMR7211, F 75013 Paris, France
    Vaccine 27:5772-80. 2009
    ..These results highlight the potential of this approach for vaccination strategies aiming at neutralizing antibody induction...
  34. pmc Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs
    Yo Hoshino
    Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland 20892, USA
    J Virol 79:410-8. 2005
    ..Given its efficacy, its defectiveness for latency, and its ability to induce rapid, virus-specific CD8(+)-T-cell responses, the dl5-29 vaccine may be a good candidate for early-phase human trials...
  35. ncbi Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes
    Judith E Epstein
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Hum Gene Ther 13:1551-60. 2002
    ....
  36. ncbi DNA vaccines for allergy treatment
    Arnulf Hartl
    University of Salzburg, Institute of Chemistry and Biochemistry, Immunology Group, Hellbrunnerstr 34, A 5020 Salzburg, Austria
    Methods 32:328-39. 2004
    ..In this paper, we describe the construction of DNA vaccines for application in allergy models...
  37. ncbi DNA vaccines: ready for prime time?
    Michele A Kutzler
    Division of Infectious Diseases and HIV Medicine, The Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA
    Nat Rev Genet 9:776-88. 2008
    ..These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic...
  38. ncbi Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections
    Francisca H C Zanin
    Faculdade de Farmacia, Universidade Federal de Minas Gerais, Avenida Antonio Carlos 6627, 31270 901 Belo Horizonte, Minas Gerais, Brazil
    Microbes Infect 9:1070-7. 2007
    ..donovani and L. mexicana (NH) infections. In this work, we investigated the protective efficacy of A2 and NH DNA vaccines, in BALB/c mice, against L. amazonensis or L. chagasi challenge infection...
  39. pmc The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
    Godwin Nchinda
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10065, USA
    J Clin Invest 118:1427-36. 2008
    b>DNA vaccines promote an immune response by providing antigen-encoding DNA to the recipient, but the efficacy of such vaccines needs improving...
  40. ncbi Construction and evaluation of DNA vaccines encoding Edwardsiella tarda antigens
    Xu dong Jiao
    Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, PR China
    Vaccine 27:5195-202. 2009
    ..Similarly, DNA vaccines based on eta6 and fliC in the form of plasmids pEta6 and pFliC induced, respectively, moderate and marginal ..
  41. ncbi DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells
    Agnete B Fredriksen
    Institute of Immunology, University of Oslo, Rikshospitalet and Rikshospitalet University Hospital, Sognsvannsvn 20, 0027 Oslo, Norway
    Mol Ther 13:776-85. 2006
    Naked DNA vaccines have a number of advantages over conventional vaccines, but induce only weak immune responses...
  42. pmc Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery
    Simon R Best
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 27:5450-9. 2009
    b>DNA vaccines are an attractive approach to eliciting antigen-specific immunity...
  43. ncbi Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma
    Fernando Abaitua
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Virus Res 116:11-20. 2006
    ..The increment of the CD8+ T cell response was higher in a DNA/MVA prime/boost protocol. Thus, the immune response of MVA vectors can be improved with the co-delivery of the cytokines IFN-gamma or IL-12...
  44. ncbi CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens ..
  45. ncbi Vaccination of mice against experimental Neospora caninum infection using NcSAG1- and NcSRS2-based recombinant antigens and DNA vaccines
    A Cannas
    Institute of Parasitology, University of Berne, Langgass strasse 122, CH 3012 Berne, Switzerland
    Parasitology 126:303-12. 2003
    ..Our results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice...
  46. ncbi Progress in DNA-based heterologous prime-boost immunization strategies for malaria
    Anne C Moore
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Immunol Rev 199:126-43. 2004
    ..Despite success in small animal models, DNA vaccines fail to induce strong cellular immune responses in humans...
  47. ncbi DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice
    S M Costa
    Laboratory of Immunopathology, Department of Bichemistry and Molecular Biology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Pav Leonidas Deane, s 204, Rio de Janeiro, RJ, CEP 21040 900, Brazil
    Virology 358:413-23. 2007
    We analyzed four DNA vaccines based on DENV-2 NS1: pcENS1, encoding the C-terminal from E protein plus the NS1 region; pcENS1ANC, similar to pcENS1 plus the N-terminal sequence from NS2a (ANC); pcTPANS1, coding the t-PA signal sequence ..
  48. ncbi Chemical adjuvants for plasmid DNA vaccines
    John R Greenland
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Research East 113, Boston, MA 02215, USA
    Vaccine 25:3731-41. 2007
    Plasmid DNA vaccines are a promising modality for immunization against a variety of human pathogens...
  49. pmc Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys
    Norman L Letvin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1530-3. 2006
    ..These immune correlates of vaccine efficacy should guide the evaluation of AIDS vaccines in humans...
  50. pmc Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein
    J G Valenzuela
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Dr, Rm. 4/126, Bethesda, MD 20892, USA
    J Exp Med 194:331-42. 2001
    ..These results indicate that DTH response against saliva provides most or all of the protective effects of this vaccine and that salivary gland proteins or their cDNAs are viable vaccine targets against leishmaniasis...
  51. ncbi Jump-starting the immune system: prime-boosting comes of age
    David L Woodland
    Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA
    Trends Immunol 25:98-104. 2004
    ..This Review discusses the impact of these recent developments on the future of prime-boost vaccine strategies...
  52. pmc Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks
    Mengji Lu
    Institut fur Virologie, Universitatsklinikum Essen, Hufelandstrasse 55, Essen D 45122, Germany
    J Virol 79:6368-76. 2005
    A number of options are available to modify and improve DNA vaccines. An interesting approach to improve DNA vaccines is to fuse bioactive domains, like cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4), to an antigen...
  53. ncbi Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response
    I Ramos
    Centro de Investigaciones Biologicas, Spanish Research Council, Ramiro de Maeztu 9, 28040 Madrid, Spain
    Vaccine 26:333-44. 2008
    ....
  54. ncbi Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina
    W Min
    Parasite Biology, Epidemiology, Systematics Laboratory, Animal and Natural Resources Institute, BARC-East, Building 1040, US Department of Agriculture, Beltsville, MD 20705, USA
    Vaccine 20:267-74. 2001
    ..These results indicate that the type and the dose of cytokine genes injected into chickens influence the quality of the local immune response to DNA vaccination against coccidiosis...
  55. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
    ..DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells...
  56. ncbi Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK
    Maria J Ramiro
    Centro de Investigaciones Biologicas, Velazquez 144, CSIC, Madrid 28006, Spain
    Vaccine 21:2474-84. 2003
    ..This type of DNA/rVV prime/boost immunization approach may have utility against visceral leishmaniasis in dogs...
  57. pmc Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection
    Nisha Garg
    Center for Tropical and Emerging Infectious Diseases and Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA
    Infect Immun 70:5547-55. 2002
    ..cruzi infection. In addition, this work provides the first evidence that prophylactic genetic immunization can prevent the development of Chagas' disease...
  58. ncbi Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help
    Michele A Kutzler
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 175:112-23. 2005
    b>DNA vaccines are a promising technology for the induction of Ag-specific immune responses, and much recent attention has gone into improving their immune potency...
  59. ncbi Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity
    Barry S Peters
    Kings College London, UK
    Vaccine 25:2120-7. 2007
    ..Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA)...
  60. ncbi Is genetic vaccination against allergy possible?
    Richard Weiss
    Department of Molecular Biology, Division of Allergy and Immunology, University of Salzburg, Salzburg, Austria
    Int Arch Allergy Immunol 139:332-45. 2006
    ..b>DNA vaccines can also be applied as mixtures of single vaccines, making them interesting candidates for treatment based on ..
  61. pmc Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice
    Eric Dumonteil
    Laboratorio de Parasitologia, Centro de Investigaciones Regionales Dr Hideyo Noguchi, Universidad Autonoma de Yucatan, Merida, Yucatan, Mexico
    Infect Immun 72:46-53. 2004
    ..Because of the potential of DNA vaccines for immunotherapy of chronic and infectious diseases, we tested if DNA vaccines could control an ongoing ..
  62. ncbi Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice
    I Nobiron
    Department of Pathology and Infectious Diseases, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK
    Vaccine 19:4226-35. 2001
    ..The need for an adjuvant in this system was emphasised by the MHC restriction observed when C57BL/6 mice (H2-kb) were immunised with the E2 DNA construct. Antibody levels were dramatically lower in this mouse strain...
  63. ncbi A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins
    Elena Quaglino
    Molecular Biotechnology Center, University of Torino, Torino, Italy
    Cancer Res 70:2604-12. 2010
    ....
  64. ncbi Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases
    Richard Weiss
    Department of Molecular Biology, University of Salzburg, A 5020 Salzburg, Austria
    Curr Drug Targets Inflamm Allergy 4:585-97. 2005
    ..This review gives an overview on the current status of allergy DNA vaccines and presents advances in the design of vaccine constructs...
  65. pmc Control of human mesothelin-expressing tumors by DNA vaccines
    C L Chang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:1189-98. 2007
    ..Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity...
  66. pmc Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3
    Marta Romano
    Mycobacterial Immunology, Pasteur Institute, Wetenschappelijk Instituut voor Volksgezondheid, Brussels, Belgium
    Immunology 118:321-32. 2006
    b>DNA vaccines encoding the 32,000 MW mycolyl-transferase Ag85A and the 40,000 MW phosphate-binding protein PstS-3 can elicit protective immune responses against experimental infection with Mycobacterium tuberculosis in C57BL/6 mice...
  67. pmc A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis
    Margot A Skinner
    AgResearch, Wallaceville Animal Research Centre, Upper Hutt, New Zealand
    Infect Immun 71:4901-7. 2003
    ..was investigated in cattle naturally sensitized to environmental mycobacteria by using a combination of three DNA vaccines coding for Hsp 65, Hsp 70, and Apa for priming, followed by a boost with BCG prior to experimental challenge ..
  68. ncbi Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters
    Kristin W Spik
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Vaccine 26:5177-81. 2008
    To determine if DNA vaccines for two hantaviruses causing hemorrhagic fever with renal syndrome, Hantaan virus and Puumala virus, are immunogenic when given in combination, we delivered them to hamsters separately or as mixtures by gene ..
  69. ncbi Current progress of DNA vaccine studies in humans
    Shan Lu
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, LRB 304, Worcester, MA 01605, USA
    Expert Rev Vaccines 7:175-91. 2008
    ..Although clinical trials conducted so far have provided overwhelming evidence that DNA vaccines are well tolerated and have an excellent safety profile, the early designs of DNA vaccines failed to ..
  70. ncbi Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston 02215, USA
    Eur J Immunol 34:1011-20. 2004
    The immunogenicity of plasmid DNA vaccines may be limited by the availability of professional antigen-presenting cells (APC) at the site of inoculation...
  71. pmc Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St, Room 480, Baltimore, Maryland 21201, USA
    J Virol 83:2789-94. 2009
    ..We developed two Sindbis virus DNA vaccines encoding the measles virus hemagglutinin (pMSIN-H) and fusion proteins (pMSINH-FdU) and examined their ..
  72. ncbi Assuring the quality, safety, and efficacy of DNA vaccines
    J S Robertson
    National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK
    Mol Biotechnol 17:143-9. 2001
    ..This paper examines the regulatory process with respect to the development of a DNA vaccine. DNA vaccines present unusual safety considerations that must be addressed during preclinical safety studies, including ..
  73. ncbi Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines
    T Coates
    The Queen Elizabeth Hospital, Woodville, South Australia
    Clin Ther 23:392-403. 2001
    ..Ideally, younger populations should be a primary target in current universal vaccination programs...
  74. pmc A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
    S J Dunachie
    University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
    Infect Immun 74:5933-42. 2006
    ..033). No protection was observed in the DDM-CS group. Prime-boost vaccination with DNA and MVA encoding ME-TRAP but not CS resulted in partial protection against P. falciparum sporozoite challenge in the present study...
  75. ncbi Vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), with recombinant and DNA vaccines produced to Flavobacterium psychrophilum heat shock proteins 60 and 70
    K P Plant
    Hagerman Fish Culture Experiment Station, University of Idaho, Hagerman, ID, USA
    J Fish Dis 32:521-34. 2009
    ..Although Hsps of F. psychrophilum have been shown to be immunodominant, these antigens do not appear to be good vaccine candidates when delivered alone or in combination...
  76. ncbi A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2
    Ho Tsun Wong
    Department of Biology, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China
    Vaccine 20:2641-7. 2002
    ....
  77. pmc DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection
    L Planelles
    , , CSIC, 18001 Granada, Spain
    Infect Immun 69:6558-63. 2001
    ..Moreover, protection against the parasite challenge was observed after immunization with the chimeric gene...
  78. ncbi [DNA vaccines and recombinant antigens in prevention of Toxoplasma gondii infections--current status of the studies]
    Elzbieta Hiszczynska-Sawicka
    Katedra Mikrobiologii, Politechnika Gdanska, ul G Narutowicza 11 12, 80 952 Gdansk
    Wiad Parazytol 55:125-39. 2009
    ..The article presents the current status of vaccine strategies against toxoplasmosis with focus on the most developed approaches using naked DNA and recombinant antigens...
  79. ncbi Protection from pathogenic SIV challenge using multigenic DNA vaccines
    N L Haigwood
    Seattle Biomedical Research Institute, WA 98109, USA
    Immunol Lett 66:183-8. 1999
    ..Multigenic DNA vaccines such as these, bearing all structural and regulatory genes, show significant promise and may be a safe ..
  80. ncbi Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site
    Eric Rowcliffe
    Department of Clinical Virology, University of Goteborg, Guldhedsgatan IOB, S 41346, Goteborg, Sweden
    Scand J Infect Dis 36:360-4. 2004
    HIV-1 env based DNA vaccines are generally found to be poor B-cell immunogens. We examined the role of an N-glycan located in the V3 loop of HIV-1 (N306) that is known to modulate the immunogenicity of gp120...
  81. ncbi Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, Pennsylvania 19486, USA
    J Pharm Sci 93:1924-39. 2004
    ..These results indicate that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys...
  82. ncbi Tolerizing DNA vaccines for autoimmune arthritis
    Peggy P Ho
    Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Autoimmunity 39:675-82. 2006
    ..In this paper we describe development of antigen-specific tolerizing DNA vaccines to treat collagen-induced arthritis (CIA) in mice, and use of protein microarrays to monitor response to ..
  83. ncbi Accelerated immune response to DNA vaccines
    Lei Zhang
    Genetronics, Inc, San Diego, California 92121, USA
    DNA Cell Biol 22:815-22. 2003
    b>DNA vaccines offer considerable promise for improvement over conventional vaccines. For the crucial step of delivering DNA vaccines intracellularly, electroporation (EP) has proven to be highly effective...
  84. ncbi Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever
    D B Wallace
    Onderstepoort Veterinary Institute, Onderstepoort, South Africa
    Vaccine 24:7181-9. 2006
    ..Vaccinated sheep sero-converted for both viruses and were protected against RVFV challenge, however, neither the immunised or negative control animals showed any significant reactions to the virulent SPV challenge...
  85. ncbi Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis
    S J Ha
    Department of Life Science, Pohang University of Science and Technology, Pohang, Korea
    Gene Ther 10:1592-9. 2003
    ....
  86. ncbi Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    J Infect Dis 186:1065-73. 2002
    ....
  87. pmc Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines
    Wing Pui Kong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 77:12764-72. 2003
    ..Such combinations of immunogens may help to address concerns about viral genetic diversity for a prospective HIV-1 vaccine...
  88. ncbi Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice
    C L Silva
    REDE TB, Departamento de Bioquimica e Imunologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil
    Gene Ther 12:281-7. 2005
    ....
  89. ncbi Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
    T Hanke
    Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, UK
    Immunol Lett 66:177-81. 1999
    ..Thus, a vaccination regimen for an effective elicitation of CTL has been developed which might facilitate evaluation of the role(s) that these lymphocytes play in the control of SIV and HIV infections...
  90. ncbi DNA vaccines for the treatment of prostate cancer
    Sheeba Alam
    Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA
    Expert Rev Vaccines 9:731-45. 2010
    ..b>DNA vaccines represent one vaccine approach that has been evaluated in multiple preclinical models and clinical trials...
  91. ncbi Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines
    Yinchang Zhu
    Jiangsu Institute of Parasitic Diseases, Key Laboratory on Technology for Parasitic Disease Prevention and Control, Ministry of Health, 117 Yangxiang Meiyuan, Wuxi 214064, Jiangsu, China
    Vaccine 28:5347-55. 2010
    ..Our results suggest that the combination of a codon optimized vaccine design and an efficient vaccine delivery system can greatly improve the potential of a SjTPI DNA vaccine as a viable schistosome vaccine candidate...
  92. ncbi Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection
    Florence Faurez
    French Food Safety Agency Afssa, Viral Genetics and Biosafety Unit, Fr 22440, Ploufragan, France
    Vaccine 28:3888-95. 2010
    ..Much work is also being dedicated to develop effective DNA vaccines for humans...
  93. pmc Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model
    Rakhee Sachdeva
    Department of Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    PLoS ONE 4:e7880. 2009
    ..In this study we have compared immunogenicity and efficacy of three types of DNA vaccines: single antigen Gp63 (Gp63/pcDNA), polytope (Poly/pcDNA) and Polytope fused with hsp70 (Poly/hsp/pcDNA) against ..
  94. ncbi Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes
    Dongzhi Cen
    Institute of Hematology, Medical College, Jinan University, Guangzhou, China
    Hematology 15:88-95. 2010
    ..Our results indicate that a DNA vaccine with PML fusion gene segment and hIL-2 together might elicit increased cellular immune responses in mice...
  95. ncbi DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice
    A Amici
    General Physiology Laboratory of Genetic Immunization, Department of Biology MCA, University of Camerino, Camerino, Italy
    Gene Ther 7:703-6. 2000
    ..Our data demonstrate the effectiveness of DNA vaccination using truncated Neu plasmids in inducing antitumor protection in a spontaneous mammary tumor model...
  96. ncbi Efficacy of DNA vaccines carrying Eimeria acervulina lactate dehydrogenase antigen gene against coccidiosis
    Hongyan Song
    College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu 210095, PR China
    Exp Parasitol 126:224-31. 2010
    The efficacies of DNA vaccines encoding either Eimeria acervulina lactate dehydrogenase (LDH) antigen or a combination of LDH antigen and chicken IL-2 or IFN-gamma were evaluated against chicken coccidiosis...
  97. ncbi DNA vaccines: precision tools for activating effective immunity against cancer
    Jason Rice
    Genetic Vaccine Group, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK
    Nat Rev Cancer 8:108-20. 2008
    ..Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer.
  98. pmc DNA vaccines: developing new strategies against cancer
    Daniela Fioretti
    Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council CNR, Via Fosso del Cavaliere 100, 00133 Rome, Italy
    J Biomed Biotechnol 2010:174378. 2010
    Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer...
  99. ncbi DNA vaccines and their applications in veterinary practice: current perspectives
    K Dhama
    Division of Pathology, Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122, India
    Vet Res Commun 32:341-56. 2008
    ..The potential of DNA vaccines to act in presence of maternal antibodies, its stability and cost effectiveness and the non-requirement of cold ..
  100. pmc Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines
    William Dowling
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, MD 21702, USA
    J Virol 81:1821-37. 2007
    ..We measured the influences of GP glycosylation on antigenicity, immunogenicity, and protection by testing DNA vaccines comprised of GP genes with deleted N-linked glycosylation sites or with deletions in the central hypervariable ..
  101. ncbi Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis
    Manuela Pardini
    Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanita, Rome, Italy
    FEMS Microbiol Lett 262:210-5. 2006
    ..97 log10 CFU decrease). Multipromoter plasmids, which permit the reduction of the total amount of DNA injected, can be useful for DNA vaccination against tuberculosis...

Research Grants66

  1. Novel DNA-Launched Attenuated Vaccine for VEE Virus
    PETER M PUSHKO; Fiscal Year: 2012
    ..This technology also utilizes many advantages of DNA vaccines (genetic homogeneity and stability, low cost of manufacturing, storage, and transportation, no cold chain) and, ..
  2. Recombinant Attenuated Salmonella Vaccines for Humans
    Roy Curtiss; Fiscal Year: 2012
    ..Salmonella vaccine (RASV) vectors to deliver after needle-free oral inoculation protective antigens and/or DNA vaccines to stimulate mucosal, systemic and cellular immunities against bacterial, viral and parasite infectious disease ..
  3. Present Homologous and Heterologous Antigen with Hepatitis E Virus
    R Holland Cheng; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Advantages of DNA vaccines including well-tolerance, safety and ability to induce antibody, cytotoxic T- lymphocytes, and T-helper immune responses make it more and more attractive in treatment of ..
  4. Experimental Molecular Vaccines for Schistosomiasis
    Afzal A Siddiqui; Fiscal Year: 2012
    b>DNA vaccines have shown great promise in eliciting both humoral and cellular immune responses in a variety of rodent and non-human primate models...
  5. Microneedle-based immunization against pandemic influenza
    Mark R Prausnitz; Fiscal Year: 2011
    ..Virus-like particles, purified protein, and DNA vaccines against the H5 influenza strain will be delivered using microneedles to mice and hairless guinea pigs...
  6. Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine
    JAY WILLIAMS HOOPER; Fiscal Year: 2013
    ..In proof-of-concept studies, we demonstrated that these DNA vaccines, delivered alone or in combination, elicit high-titer neutralizing antibodies and confer protection in animals...
  7. Development of Breast Cancer Vaccines
    WEI ZEN NONE WEI; Fiscal Year: 2013
    PROJECT SUMMARY/ABSTRACT The goal is to use novel, yet straightforward DNA vaccines to overcome immune tolerance to tumor associated antigens, thus inducing anti-tumor immunity to provide long-term protection...
  8. Novel Tetravalent Vaccines for Dengue Virus
    ROBERT GERALD WHALEN; Fiscal Year: 2013
    ..Altravax possesses several novel dengue envelope variants that, as DNA vaccines, can individually induce neutralizing antibodies to all four dengue serotypes in monkeys...
  9. Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)
    Jacques H Grosset; Fiscal Year: 2013
    ..ulcerans for vaccine assessment and compare the efficacy of BCG, DNA vaccines and newly proposed vaccines in the prevention of M. ulcerans disease...
  10. Nanocapsule-mediated topical delivery of VLP-generating Dengue DNA vaccine
    Gretchen M Unger; Fiscal Year: 2013
    ..However, DNA vaccines have historically suffered from low immunogenicity...
  11. Integrase-defective lentiviral based influenza vaccines
    Mirella Salvatore; Fiscal Year: 2010
    A key problem in vaccine development is finding an effective way to induce cellular immunity. DNA vaccines are constituted by a plasmid encoding the target antigen under the transcriptional control of a promoter region active in human ..
  12. Topical DNA immunization by modifying the hair follicle cycle
    Zhengrong Cui; Fiscal Year: 2011
    ..The outcomes will lay a sound scientific foundation for us to improve the efficacy of topical DNA vaccines in future trials...
  13. CONTROLLED RELEASE OF MACROMOLECULES
    ROBERT SAMUEL LANGER; Fiscal Year: 2013
    ..lung-tumor cell specific DNA delivery systems for the anti-tumor therapy and 2) developing anti-lung cancer DNA vaccines by targeting and activating native immune cells. Our specific aims are: 1...
  14. Testing DNA Vaccine Against T. cruzi in Large Animal Model (Dogs)
    Nisha Jain Garg; Fiscal Year: 2010
    ..Our hypothesis is that immunization of dogs with DNA vaccines would elicit protective immunity against T...
  15. Assessment of the Immunogenicity and Protective Efficacy of a Multiagent DNA Vacc
    Connie Schmaljohn; Fiscal Year: 2010
    ..By comparison, DNA vaccines have been proven safe in many human clinical trials and there is no possibility of vector immunity...
  16. Collaborative Development of a Vaccine against Cutaneous and Visceral Leishmanias
    MARY EDYTHE WILSON; Fiscal Year: 2010
    ..from the three collaborating laboratories for protection/ cross-protection under standardized conditions using DNA vaccines made to GMP standards, and to test the top 6-10 vaccines as up to 6-valent DNA vaccines;(2) To use two well ..
  17. MOLECULAR AND CELLULAR TRANSPORT IN MUCUS
    W Mark Saltzman; Fiscal Year: 2012
    ..surface can transfect local cells, which leads to local immunity;and mucosal delivery systems that deliver DNA vaccines encoding SIV proteins can protect rhesus macaques from mucosal challenges of SIV...
  18. Protection of vaccine immunity by inhibiting Fas/FasL signaling
    Maria S Salvato; Fiscal Year: 2010
    ..Lymphocytes bearing high levels of FasL are known to suppress cell-mediated immunity and destroy the efficacy of DNA vaccines. Their ability to kill the antigen-presenting cells can be eliminated by several different mechanisms and we ..
  19. A novel DNA-launched live attenuated Chikungunya vaccine
    PETER M PUSHKO; Fiscal Year: 2012
    ..Experimental CHIKV i-DNA vaccines will be evaluated in vitro and in vivo along with the current 181/25 live attenuated vaccine...
  20. Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio
    Connie Schmaljohn; Fiscal Year: 2013
    ..Despite these attributes, DNA vaccines have not achieved routine usage in large part due to poor immunogenicity related to ineffective delivery ..
  21. Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants
    Timothy R Fouts; Fiscal Year: 2012
    ..and LT (LTA1) have demonstrated particular promise as genetic adjuvants that can enhance the immunogenicity of DNA vaccines in small and large animals and may provide necessary boosting and dose sparing effects in humans...
  22. Multiple Approaches to Abeta Vaccination in Animal Models
    DAVID HASTINGS CRIBBS; Fiscal Year: 2013
    ..In this competitive renewal the goals are to design multi-epitope anti-[unreadable]-syn DNA vaccines and test their therapeutic potential in Tg models that develop human-like neuronal [unreadable]-syn pathology ..
  23. DNA sensors and associated signaling pathways in the innate immune response
    Katherine A Fitzgerald; Fiscal Year: 2013
    ..is central not only to anti-microbial host defenses but is also a major contributor to the adjuvant activity of DNA vaccines as well as the pathology associated with autoimmune diseases such as Systemic Lupus Erythematosis...
  24. DNA vaccines for metastatic breast cancer at old age
    Claudia Gravekamp; Fiscal Year: 2010
    ..of this proposal are (1) Improvement of DNA delivery systems and protein expression in vivo;(2) Development and testing of multiantigen DNA vaccines;and (3) Testing tumor-immunological parameters in young and old mice.
  25. Vaccination strategies against pulmonary tuberculosis
    ALISTAIR JOHN RAMSAY; Fiscal Year: 2010
    ..We have recently shown that consecutive immunization with DNA vaccines and attenuated fowlpoxvirus vectors encoding similar vaccine antigens generates high levels of antigen-specific,..
  26. Improved Vaccines for Rift Valley Fever Virus
    Mark T Heise; Fiscal Year: 2010
    ..and performed preliminary analysis of two RVFV vaccines based on either alphavirus replicon particles or DNA vaccines expressing secreted forms of the RVFV glycoproteins linked to the C3d molecular adjuvant...
  27. Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
    Sue fen Kwa; Fiscal Year: 2013
    ..to express proteins that form non-infectious virus like-particles (VLP) displaying trimeric gp160 envelope (DNA vaccines) or trimeric gp150 envelope (MVAVLP)...
  28. Novel Mucosal Adjuvant for an HIV DNA Vaccine
    Kenneth C Bagley; Fiscal Year: 2010
    ..The objective of this project is to develop novel mucosal adjuvants that will improve the efficacy of HIV DNA vaccines. These adjuvants will be based on a constructs such as a dominant-positive retinoic acid receptor and the ..
  29. Elicitation of broad immunity using VLPs with consensus envs
    Ted Ross; Fiscal Year: 2009
    ..S. Food and Drug Administration guidelines for the use of HIV-1 DNA vaccines for human use. In this proposal, gene inserts expressing SHIV VLPs will be expressed from DNA...
  30. Translational linkage strategies for DNA vaccines against cancer
    ERIC S ALONZO; Fiscal Year: 2010
    ..Specific Aim 3 evaluates whether multi-copy DNA microbial fusion vaccines are effective, as combinatorial agents that can be applied with an IL-12/Fc fusion DNA construct against different tumors. ..
  31. Enhancing HPV-16 E6/E7 Specific Antitumor Immunity
    Tzyy Choou Wu; Fiscal Year: 2013
    ..It has become apparent that the poor immunogenicity of naked DNA vaccines in patients reflects inefficient delivery of the antigenic gene to professional antigen-presenting cells, ..
  32. Androgen receptor targeted vaccines for prostate cancer
    Douglas G McNeel; Fiscal Year: 2013
    ..In addition, we will evaluate whether DNA vaccines encoding hsp72 and/or a proteasome-targeting signal within a DNA vaccine can augment antigen presentation and ..
  33. NASAL DNA/PROTEIN VACCINE FOR ANTI-HIV ANTIBODY AND CTL
    Pamela Kozlowski; Fiscal Year: 2009
    ..that the parenteral adjuvant QS-21 can also be used to adjuvant immune responses to nasally administered DNA vaccines or soluble protein, and to establish an effective nasal QS-21 dosage for these vaccine preparations...
  34. Design of HIV VLPs with Enhanced Immunogenicity
    Richard W Compans; Fiscal Year: 2013
    ..Because DNA vaccines are effective in priming antibody responses as well as eliciting cellular responses (Singh et al...
  35. Rational Approach to Optimize Immune Potency of DNA Vaccines
    Nirbhay Kumar; Fiscal Year: 2013
    ..application we propose to assess cellular, molecular and immune correlates of efficacy and safety of modified DNA vaccines using a well characterized malaria vaccine candidate, Pfs25, as a model immunogen...
  36. Biodegradable Polymers For DNA Vaccine Delivery
    Chun Wang; Fiscal Year: 2012
    ..2) We will investigate systematically the in vivo mechanisms of the block polymers carrying model DNA vaccines, quantify and track the time course of critical molecular and cellular events during immune activation, using ..
  37. DNA Vaccine for Induction of Mucosal Immunity
    David B Weiner; Fiscal Year: 2013
    ..that will address the following questions: First, will delivery of chemokine immunoadjuvants systemically by DNA vaccines induce antigen specific immune responses in mucosal sites, and secondly, can mucosal-derived chemokine-induced ..
  38. Polymer Based Gene Delivery
    Alexander V Kabanov; Fiscal Year: 2010
    ..the mechanism by which Pluronic enhances transgene expression, and 3) to evaluate this system for delivery of DNA vaccines targeting malignant melanoma...
  39. A Tetravalent Dengue Vaccine Based on Alphavirus Replicons
    Laura J White; Fiscal Year: 2012
    ..b>DNA vaccines for DEN are likely to circumvent the maternal antibody problem, but DNA vaccines generally have been ..
  40. Correlates of protection against SIV/SHIV challenge
    Hildegund C J Ertl; Fiscal Year: 2010
    ..3 will determine immune responses elicited by different prime-boost vaccine regimens using combinations of DNA vaccines, E1-deleted adenovirus (Ad) vectors and poxvirus vectors...
  41. DNA Vaccine for Seasonal &Pandemic Influenza
    Deborah H Fuller; Fiscal Year: 2011
    ..This proposal will develop a DNA vaccine to meet these needs. DNA vaccines can be rapidly designed and manufactured to express multiple antigens and induce antibody and cell-mediated ..
  42. A SARS-CoV Spike Protein Vaccine
    B Sim; Fiscal Year: 2005
    ..information leads to enhanced expression of recombinant proteins and in vivo expression of proteins by DNA vaccines. We therefore will use the Region I Spike Protein SARS-CoV native no glycosylation (RI-native-NG) sequence as ..
  43. Programmable Mesocomposites for Controlled and Cell-targeted DNA Delivery
    Hong Shen; Fiscal Year: 2009
    ..application can be directly translated to a variety of clinical settings, including cancer gene therapy and DNA vaccines. Our inter-related three aims would demonstrate the value of programmable materials in complicated biological ..
  44. Novel approaches for vaccine design
    Michel C Nussenzweig; Fiscal Year: 2013
    ..Specific aims are: 1) Develop DNA vaccines that incorporate dendritic cell targeting strategies and test the vaccines in humans 2) Regulate FcR signaling ..
  45. Impedance Changes as an Indicator of Successful Skin Electroporative DNA delivery
    Mark J Jaroszeski; Fiscal Year: 2012
    ..It has been investigated as a delivery method for DNA vaccines, cancer treatment, and the management of metabolic diseases with much success in preclinical studies...
  46. Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer
    Douglas McNeel; Fiscal Year: 2009
    ..antigens for inclusion in prostate cancer vaccines, target these antigens in rodent models using plasmid DNA vaccines, and ultimately to translate these findings to human clinical testing in patients with prostate cancer...
  47. Falciparum malaria invasion ligand DNA/protein vaccine
    David Narum; Fiscal Year: 2002
    ..We have experience with DNA vaccines and GMP experience with a high yield P. pastoris recombinant expression system...
  48. Development of Streamed Ion Deposition for Efficient Plasmid DNA Delivery
    Mark J Jaroszeski; Fiscal Year: 2011
    ..In addition, it may lead to a better means of applying DNA vaccines against infectious diseases.
  49. Adjuvants for Agile Vaccine Development
    Philip Felgner; Fiscal Year: 2006
    ..Furthermore, the potency of DNA vaccines can be increased by boosting with recombinant viruses or proteins, and the "Prime-Boost" approach is becoming ..
  50. ECOLOGY OF HANTAVIRUS ENZOOTICS: IMMUNE INTERVENTIONS
    Brian Hjelle; Fiscal Year: 2001
    ..an excellent model organism for situations in which rapid development and deployment of empirically-designed DNA vaccines could be used to intervene in an outbreak caused by newly-emerged or poorly- characterized pathogens...
  51. DEVELOP AND EVALUATE NEW LEPROSY AND TB VACCINES
    Thomas Gillis; Fiscal Year: 2003
    ..leprae with DNA vaccines and TB vaccines will (1) elicit a measurable immune response to appropriate antigens of M...
  52. DEVELOPMENT OF ROTAVIRUS DNA VACCINES
    John Herrmann; Fiscal Year: 2003
    DESCRIPTION: (Adapted from Applicant's Abstract) The goal of our studies is to develop and test rotavirus DNA vaccines in mice and gnotobiotic pigs that will provide the basis for development of human rotavirus DNA vaccines...
  53. Dendritic Cell Targeting of Lassa Fever Vaccine
    Maria Salvato; Fiscal Year: 2005
    Our goal is to enhance the efficacy of DNA vaccines using new bio-organic compounds to mediate delivery...
  54. Development of a Malaria DNA Vaccine with Enchanced Immunogenicity
    Richard Markham; Fiscal Year: 2009
    Although DNA vaccines offer many advantages, their inability to elicit sustained protective immune responses in non-human primates and humans has been disappointing...
  55. VACCINATION AGAINST S MANSONI WITH STPI AND SM23
    Donald Harn; Fiscal Year: 2001
    ..In regards to DNA vaccines, we will test efficacy of two DNA vaccines based on sTPI coding regions, one of which is the coding region for ..
  56. FALCIPARUM MALARIA INVASION LIGAND VACCINE NE
    B Sim; Fiscal Year: 1999
    ..In Phase II we will also produce DNA vaccines based on the peptide 4 region of EBA-175, a region which had been shown to induce antibodies with inhibitory ..
  57. DNA VACCINE IMMUNITY TO HIV1 AND SIV
    Norman Letvin; Fiscal Year: 2002
    ..This study will also explore the use of B7.1 and B7.2 as DNA constructs in immune response induction by DNA vaccines. (1) Use of IL-2/Ig as a protein or DNA plasmid to augment plasmid DNA vaccine- elicited HIV-l Env specific ..
  58. THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA
    Peter Hobart; Fiscal Year: 2000
    ..We also anticipate that success of this therapeutic vaccine will lead to the use of DNA vaccines to treat a wide range of human cancers...
  59. Non-Viral Delivery of DNA Vaccines to the Buccal Mucosa
    Maria Salvato; Fiscal Year: 2003
    Our goal is to enhance the efficacy of DNA vaccines using new bio-organic compounds to mediate oral deliver...
  60. Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)
    T C Wu; Fiscal Year: 2009
    ..b>DNA vaccines targeting these key smallpox antigens represent a potentially plausible approach for the control of smallpox ..
  61. Novel DNA/VLP Vaccines Against Influenza
    Chinglai Yang; Fiscal Year: 2007
    ..Our group has been focused on developing strategies to enhance immune responses induced by DNA vaccines as well as VLP (virus-like particle) vaccines...
  62. ADVANCES IN DNA VACCINES AGAINST EBOLA & DENGUE VIRUSES
    J August; Fiscal Year: 2001
    Two novel advances of this and associated laboratories underlie the application of this research to DNA vaccines against Ebola and dengue viruses, and potentially other emerging viruses: (1) The coupling of the targeting sequence of ..
  63. BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA
    Myron Levine; Fiscal Year: 2004
    ..To optimize the priming potential of Shigella live vectors harboring DNA vaccines, we propose to use DNA vaccines in which codon usage has been optimized for expression by mammalian (human) ..
  64. A Novel Immune Modulator/ Adjuvant for HIV Vaccines
    William Raschke; Fiscal Year: 2009
    ..Furthermore, DNA vaccines offer an effective method of delivering multiple immunogens/epitopes representing a single or several pathogens...
  65. RECOMBINANT MALARIA INVASION LIGAND PROTEIN VACCINE
    B Sim; Fiscal Year: 2001
    ..Region II DNA vaccines induce antibodies that block EBA-175 binding to RBCs and inhibit Pf invasion of RBCs...
  66. TNT: Targeting and Triggering Adjuvancy of DNA Vaccines
    Michele Kutzler; Fiscal Year: 2005
    ..Taken together, this proposal aims to identify and characterize a unique TNT adjuvant combination for HIV-1 DNA vaccines resulting in enhanced antigen specific cell-mediated immune responses and improved HIV-1 DNA vaccine candidates. ..